Patents related to dengue virus infection

Bibliography

• RICE CM: Flaviviridae: the viruses and their replication. In: Fields Virology 3rd edn, Fields BN, Knipe DM, Howley PM (Ed.), Lippincott-Raven, Philadelphia (1996):931–959.
   Google Scholar
• ASHBURN PM, CRAIG CF: Experimental investigations regarding the etiology of dengue fever." Infect. Disease. (1907) 4:440–475.
   PubMedGoogle Scholar
• MONATH TP, HEINZ FX: Flaviviruses. In: Fields Virology 3rd edn. Fields BN, Knipe DM, Howley PM (Ed), Lippincott-Raven, Philadelphia (1996):1961–1034.
   Google Scholar
• HOWARD CR: Viral hemorrhagic fevers: properties and prospects for treatment and prevention. Antiviral Res. (1984) 4:169–186.
   PubMedGoogle Scholar
• MILLER RH, PURCELL RH: Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc. Natl Acad. Sci. USA (1990) 87(6):2057–2061.
   PubMed Web of Science ®Google Scholar
• MCHUTCHISON JG, GORDON SC, SCHIFF ER: Interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Eng. Med. (1998) 339 (21):1485–1492.
   Google Scholar
• KOFF WC, ELM JL, HALSTEAD SB: Antiviral effects if ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro. Antiviral Res. (1982) 2(1-2):69–79.
   PubMedGoogle Scholar
• MALINOSKI FJ, HASTY SE, USSERY MA, DALRYMPLE JM: Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. (1990) 13(3):139–149.
   PubMedGoogle Scholar
• MURTHY HM, CLUM S, PADMANABHAN R: Dengue virus N53 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. (1999) 274(9):5573–5580.
   Google Scholar
• BRINKWORTH RI, FAIRLIE DP, LEUNG D, YOUNG PR: Homology model of the dengue 2 virus N53 protease: putative interactions with both substrate and NS2B cofactor.j Gen. Virol. (1999) 80(5):1167–1177.
   Google Scholar
• STRAUSS JH, STRAUSS EG: Virus evolution: how does an enveloped virus make a regular structure? Cell (2001) 105(1):5–8.
   PubMed Web of Science ®Google Scholar
• BANCROFT TL: On the aetiology of dengue fever. Aust. Med. Gazette (1906) 25:17–18.
   Google Scholar
• •Of historic interest.
   Google Scholar
• SILER JF, HITCHENS AP: Dengue: its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philli pine ScL (1926) 29(1-2):1–304.
   Google Scholar
• ••Extraordinary clinical research definingmode of transmission and clinical spectrum of dengue virus infection.
   Google Scholar
• MONATH TP: The arboviruses: ecology and epidemiology. Monath TP: (Ed) CRC Press, Boca Raton, Florida (1988).
   Google Scholar
• HALSTEAD SB: Pathogenesis of dengue: challenges to molecular biology. Science (1988) 239(4839):476–481.
   PubMed Web of Science ®Google Scholar
• HALSTEAD SB: The XXth century dengue pandemic: need for surveillance and research. World Health Stat. Q. (1992) 45(2-3):292–298.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANIZATION: Dengue and dengue hemorrhagic fever. WHO Report N117(1996).
   Google Scholar
• DURBIN AP, KARRON RA, SUN W et al.: Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am. I Trop. Med. Hyg. (2001) 65(5):405–413.
   PubMed Web of Science ®Google Scholar
• SHARP TW: Dengue fever in US troops during operation restore hope, Somalia, 1992-1993. Am..! Trop. Med. Hyg. (1995) 53(1):89–94.
   PubMedGoogle Scholar
• MONATH TP: Dengue: the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA (1994) 91(7):2395–2400.
   PubMedGoogle Scholar
• MELTZER MI: Assessing the global economic impact of dengue and DHE Am. Trop. Med. Hyg. (1998) 59(3):157.
   Google Scholar
• MELTZER MI, RIGAU-PEREZ JG, CLARK GG, REITER P, GUBLER DJ: Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am. J. Trop. Med. Hyg. (1998) 59(2):265–271.
   PubMedGoogle Scholar
• RIGAU-PEREZ R: The emergence of dengue hemorrhagic fever as a threat to public health in Puerto Rico. Am. j Trop. Med. Hyg. (1996) 55(2):50.
   PubMedGoogle Scholar
• INNIS BL: Dengue and dengue hemorrhagic fever. In: Exotic viral infections Porterfield JS (Ed), Chapman & Hall, London (1995):103–146.
   Google Scholar
• ••Outstanding review of dengue virus andclinical disease.
   Google Scholar
• CLARK G: Public-private partnerships to develop and implement community-based prevention programs. Am." Trop. Med. Hyg. (1996) 55(2):50.
   Google Scholar
• HENCHAL EA, PUTNAK JR: The dengue viruses. Clin. Microb. Rev (1990) 3(4):376–396.
   PubMedGoogle Scholar
• SIMMONS JS, JOHN ST, REYNOLDS FHK: Experimental studies of dengue. Phillipine Sci. (1931) 44(1-22):1–252.
   Google Scholar
• ••Extraordinary clinical research definingmode of transmission and clinical spectrum of dengue virus infection.
   Google Scholar
• QUINTOS FN: Hemorrhagic fever observed among children in the Philippines. Philippine Pediat. (1954) 3:1–9.
   Google Scholar
• JATANASEN S, SAKUNTANAGA P, DHANASIRI C: Some aspects of epidemiology of Thai hemorrhagic fever 1958–1961. In: Thai Hemorrhagic Fever Symposium. Bangkok. SEATO Medical Research Monograph (1961).
   Google Scholar
• HAMMON WM, RUDNICK A, SATHER GE: Viruses associated with hemorrhagic fever of the Philippines and Thailand. Science (1960) 131:1102–1103.
   PubMed Web of Science ®Google Scholar
• TECHNICAL ADVISORY COMMITTEE: Dengue hemorrhagic fever: diagnosis, treatment and control. WHO, Geneva, Switzerland (1986).
   Google Scholar
• WORLD HEALTH ORGANIZATION: Technical guides for diagnosis, treatment,surveillance, prevention and control of dengue haemorrhagic fever. WHO, Geneva (1975).
   Google Scholar
• BHAMARAPRAVATI N, TUCHINDA P, BOONYAPAKNAVIK V: Pathology of Thailand hemorrhagic fever: a study of 100 autopsy cases. Am. J. Trop. Med. Parasitol (1967) 61(4):500–510.
   PubMed Web of Science ®Google Scholar
• INNIS BL: Acute liver failure is one important cause of fatal dengue infection. South East Asian I. Trop. Med. Public Health (1990) 21:695–696.
   Google Scholar
• ROSEN L, DROUET MT, DEUBEL V: Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. Am. I Trop. Med. Hyg. (1999). 61(5):720–724.
   PubMed Web of Science ®Google Scholar
• HALSTEAD SB, NIMMANNITYA S, MARGIOTTA MR: Dengue and chikungunya virus infection in man in Thailand, 1962-1964. II. Observations on disease in outpatients. Am. I Trop. Med. Hyg. (1969) 18(6):972–983.
   PubMedGoogle Scholar
• HALSTEAD SB, UDOMSAKDI S, SINGHARAJ P, NISALAK A: Dengue chikungunya virus infection in man in Thailand, 1962-1964. Clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. Am. J. Trop. Med. Hyg. (1969) 18(6):984–996.
   Google Scholar
• HALSTEAD SB, SCANLON JE, UMPAIVIT P, UDOMSAKDI S: Dengue and chikungunya virus infection in man in Thailand, 1962-1964 IV Epidemiologic studies in the Bangkok metropolitan area. J. Trop. Med. Hyg. (1969) 18(6):997–1021.
   Google Scholar
• HALSTEAD SB, UDOMSAKDI S, SCANLON JE, ROHITAYODHIN S: Dengue and chikungunya virus infection in man in Thailand, 1962-1964. V Epidemiologic observations outside Bangkok. Am. I Trop. Med. Hyg. (1969) 18(6):1022–1033.
   PubMedGoogle Scholar
• HALSTEAD SB: Observations related topathogensis of dengue hemorrhagic fever VI. Hypotheses and discussion. Yale I. Biol. Med. (1970) 42(5):350–362.
   PubMed Web of Science ®Google Scholar
• HALSTEAD SB, NIMMANNITYA S, COHEN SN: Observations related to pathogenesis of dengue hemorrhagic fever IV Relation of disease severity to antibody response and virus recovered. Yale.! Biol. Med. (1970) 42(5):311–328.
   PubMedGoogle Scholar
• HALSTEAD SB, UDOMSAKDI S, SIMASTHIEN P, SINGHARAJ P, SUKHAVACHANA P, NISALAK A: Observations related to pathogenesis of dengue hemorrhagic fever I. Experience with classification of dengue viruses. Yale.! Biol. Med. (1970) 42(5):261–275.
   PubMedGoogle Scholar
• NIMMANNITYA S, HALSTEAD SB, COHEN SN, MARGIOTTA MR: Dengue and chikungunya virus infection in man in Thailand, 1962-1964 I. Observations on hospitalized patients with hemorrhagic fever. Arn J. Tropic. Med. Hyg. (1969) 18(6):954–971.
   PubMedGoogle Scholar
• NISALAK A, HALSTEAD SB, SINGHARAJ P, UDOMSAKDI S, NYE SW, VINIJCHAIKUL K: Observations related to pathogenesis of dengue hemorrhagic fever. 3. Virologic studies of fatal disease. Yal e Biol. Med. (1970) 42(5):293–310.
   Google Scholar
• PORTERFIELD JS: Antibody-dependent enhancement of viral infectivity. Adv. Virus. Res. (1986) 31:335–355.
   PubMed Web of Science ®Google Scholar
• HALSTEAD SB: Antibody-dependent enhancement of infection: a mechanism for indirect virus entry into cells. In: Cellular receptors for animal viruses. Wimmer E (Ed.), Cold Spring Harbor Laboratory Press, New York (1994):493–516.
   Google Scholar
• HARRIS E, VIDEA E, PEREZ L, SANDOVAL E et al.: Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am." Tropic. Med. Hyg. (2000) 63(1–2):5–11.
   Google Scholar
• VAUGHN DW, GREEN S, KALAYANAROOJ S et al: Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. Infect. Dis. (2000) 181(1):2–9.
   Google Scholar
• SCHLESINGER RW: Dengue viruses. Springer-Verlag, New York (1977).
   Google Scholar
• HALSTEAD SB, SHOTWELL H, CASALS J: Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. I Inf Dis. (1973) 128 (1):15–22.
   Google Scholar
• MARCHETTE N: Studies on the pathogenesis of dengue infection in monkeys. III. Sequential distribution of virus in primary and heterologous infection. j Inf Dis. (1973) 128(1):23–30.
   PubMedGoogle Scholar
• HALSTEAD S, SHOTWELL H, CASALS J: Studies on the pathogenesis of dengue infection in monkeys I. Clinical laboratory responses to primary infection. j In! Dis (1973) 128(1):7–14.
   Google Scholar
• WU S, GROUARD-VOGEL G, SUN W et al.: Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. (2000) 6(7):816–820.
   PubMed Web of Science ®Google Scholar
• •Study indicating dendritic cells are an important primary target cell in dengue virus infection.
   Google Scholar
• KLAGGE IM, SCHNEIDER-SCHAULIES S: Virus interactions with dendritic cells. .1 Gen. Virol (1999) 80(4):823–833.
   Google Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Ann. Rev Irnmun. (2000) 18:767–811.
   PubMed Web of Science ®Google Scholar
• MACPHERSON G, KUSHNIR N, WYKES M: Dendritic cells, B cells and the regulation of antibody synthesis. Inman°log. Rev (1999) 172:325–334.
   Google Scholar
• SCOTT PM, NISALAK A, CHEAMUDON U, SERIDHORANAKUL S, NIMMANNITYA S: Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. Infect. Dis. (1980) 141(1):1–6.
   Google Scholar
• KING AD, NISALAK A, KALAYANROOJ S et al.: B cells are the principal circulating mononuclear cells infected by dengue virus. Southeast Asian Trop. Med. Public Health. (1999) 30(4):718–728.
   PubMedGoogle Scholar
• SUMARMO SP, WURYADI S, GUBLER DJ: Clinical observations on virologically confirmed fatal dengue infections. Bullet-ha of the WHO, Jakarta, Indonesia (1983) 61:692–701.
   Google Scholar
• DINARELLO CA: Cytokines as endogenous pyrogens. ./. Infect. Diseases. (1999) 179(52):5294–304.
   Google Scholar
• HOBER D, POLI L, ROBLIN B, GESTASP et al.: Serum levels of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-113 (IL-1I3) in dengue-infected patients. Am. I Trop. Med. Hyg. (1993) 48(3):324–331.
   PubMedGoogle Scholar
• LEITMEYER KC, VAUGHN DW, WATTS DM et al: Dengue virus structural differences that correlate with pathogenesis. .1. Virol (1999) 73(6):4738–4747.
   Google Scholar
• BOONPUCKNAVIG S, BOONPUCKNAVIG V, BHAMARAPRAVATI N, NIMMANNITYA S: Immunofluorescence study of skin rash in patients with dengue hemorrhagic fever. Arch. Pathol Lab. Med (1979) 103(9):463–466.
   PubMed Web of Science ®Google Scholar
• GOLDBLUM SE, HENNIG B, JAY M, YONEDA K, MCCLAIN CJ: Tumor necrosis factor a-induced pulmonary vascular endothelial injury. Infect. Immun. (1989) 57(4):1218–1226.
   PubMedGoogle Scholar
• GOLDBLUM SE, YONEDA K, COHEN DA, MCCLAIN CJ: Provocation of pulmonary vascular endothelial injury in rabbits by human recombinant inter1eukin-113. Infect. Immun. (1988) 56 (9) :2255–2263.
   PubMedGoogle Scholar
• STEPHENS KE, ISHIZAKA A, LARRICK JW, RAFFIN TA: Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. Am. Rev Resp. Dis. (1988) 137(6):1364–1370.
   PubMedGoogle Scholar
• BALUNA R, VITETTA ES: Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology (1997) 37(2-3):117–132.
   PubMedGoogle Scholar
• KURANE I, ENNIS FA: Cytokines in dengue virus infections: role of cytokines in the pathogenesis of dengue hemorrhagic fever. Seminars Virol (1994) 5:443–448.
   Web of Science ®Google Scholar
• AVIRUTNAN P, MALASIT P, SELIGER B, BHAKDI S, HUSMANN M: Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. Immunol (1998) 161(11):6338–6346.
   Google Scholar
• SU HL: The effect of human bc1-2 and bc1- X genes on dengue virus-induced apoptosis in cultured cells. Virology (2001) 282(1):141–153.
   PubMedGoogle Scholar
• MARIANNEAU P, CARDONA A, EDELMAN L, DEUBEL V, DESPRES P: Dengue virus replication in human hepatoma cells activates NF-icB which in turn induces apoptotic cell death.' Virol (1997) 71(03244–3249.
   PubMed Web of Science ®Google Scholar
• COUVELARD A, MARIANNEAU P, BEDEL C et al.: Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Human Pathol (1999) 30(9):1106–1110.
   PubMed Web of Science ®Google Scholar
• TYLER KL, FIELDS BN: Pathogenesis of viral infections. In: Fields Virology 3rd edn. FIELDS BN, KNIPE DM, HOWLEY PM (Eds), Lippincott-Raven, Philadelphia (1996):173–217.
   Google Scholar
• HE R-T, INNIS BL, NISALAK A et al.: Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J. Med. Virol (1995) 45(4):451–461.
   PubMedGoogle Scholar
• CHEN Y, MAGUIRE T, HILEMAN RE et al.: Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. (1997) 3(8):866–871.
   PubMed Web of Science ®Google Scholar
• •Demonstration that heparan sulfate glycosarninoglycan is one important target cell receptor for dengue virus.
   Google Scholar
• ROSTAND KS, ESKO JD: Microbial adherence and invasion through proteoglycans. Infect. Immun. (1997) 65(1):1–8.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-BARRAGAN J, DEL ANGEL PM: Identification of a putative coreceptor on vero cells that participates in dengue 4 virusiInfection.Virol (2001)75:7818–7827.
   Google Scholar
• RAMOS-CASTANEDA J, IMBERT JL, BARRON BL, RAMOS C: A 65-kDa trypsin-sensitive membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells. Neurovira. (1997) 3(6):435–440.
   PubMedGoogle Scholar
• SALAS-BENITO JS, DEL ANGEL PM: Identification of two surface proteins from C6/36 cells that bind dengueType 4 virus. Virol (1997) 71(10):7246–7252.
   Google Scholar
• SODROSKI JG: HIV-1 entry inhibitors in the side pocket. Cell (1999) 99(3):243–246.
   PubMed Web of Science ®Google Scholar
• TURNER RB, WECKER MT, POHL G et al.: Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA (1999) 281(19):1797–1804.
   PubMed Web of Science ®Google Scholar
• HALSTEAD SB: Immunological parameters of togavirus disease syndromes. In: The togaviruses. Sclessinger R (Ed), Academic Press, New York (1980):107–173.
   Google Scholar
• KURANE I, ENNIS FE: Immunity and immunopathology in dengue virus infections. Seminars Immunol (1992) 4(2):121–127.
   PubMedGoogle Scholar
• KURANE I, ROTHMAN AL, LIVINGSTON PG et al.: Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch. Virol (1994) 9:59–64.
   Google Scholar
• MEDZHITOV R, JANEWAY CAJ: Innate immunity: the virtues of a nonclonal system of recognition. Cell (1997) 91(3):295–298.
   PubMed Web of Science ®Google Scholar
• GURA T: Innate immunity. Ancient system gets new respect. Science (2001) 291(5511):2068–2071.
   Google Scholar
• JOHNSON AJ, ROEHRIG JT: New mouse model for dengue virus vaccine testing.Virol (1999) 73(1):783–786.
   Google Scholar
• DIAMOND MS, ROBERTS TG, EDGIL D, LU B, ERNST J, HARRIS E: Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons.Viral. (2000) 74(11):4957–4966.
   Google Scholar
• KOCHEL TJ, RAVIPRAKASH K, HAYES CG et al.: A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 18(27):3166–3173.
   Google Scholar
• PUTNAK R, BARVIR DA, BURROUS JM et al.: Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. (1996) 174(6):1176–1184.
   PubMed Web of Science ®Google Scholar
• KANESA-THASAN N, PUTNAK JR, HOKE CHJ: New and improved vaccines for denuge, japanese encephalitis, and yellow fever viruses. In: New Generation Vaccines. Levine MM (Ed.), Marcel Dekker, New York (1997):587–606.
   Google Scholar
• •Review of vaccine candidates.
   Google Scholar
• KANESA-THASAN N, SMUCNY JJ, HOKE CH et al.: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine (2001) 19(23-24):3179–3188.
   PubMed Web of Science ®Google Scholar
• •Initial clinical trial data on immunogenicity of a potential tetravalent vaccine.
   Google Scholar
• ZENG L, FALGOUT B, MARKOFF L: Identification of specific nucleotide sequences within the conserved 3'-SL in the dengue Type 2 virus genome required for replication. J. Viral. (1998) 72(9):7510–7522.
   PubMed Web of Science ®Google Scholar
• ••Description of a virulence-attenuatingdeletion mutation to generate a potential vaccine candidate.
   Google Scholar
• HUANG CY, BUTRAPET S, PIERRO DJ et al.: Chimeric dengue Type 2 (vaccine strain PDK-53)/dengue Type 1 virus as a potential candidate dengue Type 1 virus vaccine. J. Viral. (2000) 74 (7):3020–3028.
   PubMedGoogle Scholar
• GUIRAKHOO F, ARROYO J, PUGACHEV KV et al: Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Viral. (2001) 75(107290–7304.
   Google Scholar
• •A promising chimeric virus vaccine candidate made up by combining elements of a clinically stable and effective vaccine strain of yellow fever virus and dengue virus.
   Google Scholar
• KINNEY RM, HUANG CY-H: Development of new vaccines against dengue fever and japanese encephalitis. Intervirology(2001) 44:176–197.
   PubMed Web of Science ®Google Scholar
• •Recent review of potential dengue virus vaccines.
   Google Scholar
• MARKOFF LJ, FAL GOUT BN: The family flaviviridae and its diseases. In: Exotic Viral Infections. Porterfield JS (Ed.), Chapman & Hall, London (1995):47–66.
   Google Scholar
• KUHN RJ, ZHANG W, ROSSMANN MG et al.: Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. CO(2002) 108(5):717–725.
   Google Scholar
• •Cryo-electron microscope study of the structure of dengue virus.
   Google Scholar
• REY FA, HEINZ FX, MANDL C, KUNZ C, HARRISON SC: The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 375(6529):291–298.
   PubMed Web of Science ®Google Scholar
• ••X-ray crystallographic study of thestructure of the ectodomain of tick-borne encephalitis virus envelope protein.
   Google Scholar
• STOLLAR V: Studies on the nature of dengue viruses. IV. The structural proteins of Type 2 dengue virus. Virology (1969) 39:426–438.
   Google Scholar
• ZHAO BT, PRINCE G, HORSWOOD R et al.: Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. I Viro/. (1987) 61(12):4019–4022. ma HEINZ FX, STIASNY K, PUSCHNER-AUER G et al.: Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology(1994) 198(1):109–117.
   Google Scholar
• FERLENGHI I, CLARKE M, RUTTAN T et al.: Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Ma Cell (2001) 7(3):593–602.
   PubMed Web of Science ®Google Scholar
• ANDERSON R, KING AD, INNIS BL: Correlation of E protein binding with cell susceptibility to dengue 4 virus infection.' Gen. Viral. (1992). 73(8):2155–2159.
   Google Scholar
• HASE T, SUMMERS PL, ECKELS KH: Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes. Arch. Viral. (1989) 104:129–143.
   PubMedGoogle Scholar
• STIASNY K, ALLISON SL, MARCHLER-BAUER A, KUNZ C, HEINZ FX: Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne-encephalitis virus. J. Viral. (1996) 70(11):8142–8147.
   PubMedGoogle Scholar
• VVENGLER G, VVENGLER G, GROSS HJ: Studies on virus specific nucleic acids synthesized in vertebrate and mosquito cells infected with flavivirus. Virology(1978) 89(2):423–437.
   PubMedGoogle Scholar
• CLEAVES GR, DUBIN DT: Methylation status of intracellular dengue Type 2 40S RNA. Virology (1979) 96(1):159–165.
   PubMed Web of Science ®Google Scholar
• LI H, CLUM S, YOU S, EBNER KE, PADMANABHAN R: The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus Type 2 N53 converge within a region of 20 amino acids. Virol (1999) 73(4):3108–3116.
   Google Scholar
• MURTHY HM, CLUM S, PADMANABHAN R: Dengue virus N53 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects.J Biol. Chem. (1999) 274 (9) 5573–5580 .
   Google Scholar
• •Structure of the dengue virus protease.
   Google Scholar
• JACOBS MG, ROBINSON PJ, BLETCHLYC, MACKENZIE JM, YOUNG PR: Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. FASEB (2000) 14(11):1603–1610.
   PubMedGoogle Scholar
• WINKLER G, MAXWELL SE, RUEMMLER C, STOLLAR V: Newly synthesized dengue-2 virus non-structural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. Virology (1989) 171(1):302–305.
   PubMedGoogle Scholar
• YUSOF R, CLUM S, VVETZEL M, MURTHY HM, PADMANABHAN R: Purified NS2B/N53 serine protease of dengue virus Type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids M vitro. j Biol. Chem. (2000) 275(14):9963–9969.
   PubMedGoogle Scholar
• KOoNIN EV: Computer-assisted identification of a putative methyltransferase domain in N55 protein of flaviviruses and lambda 2 protein of reovirus. J. Gen. Virology (1993) 74(4):733–740.
   PubMedGoogle Scholar
• TAN BH, FU J, SUGRUE RJ, YAP EH, CHAN YC, TAN YH: Recombinant dengue type 1 virus N55 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology (1996). 216(2):317–325.
   PubMedGoogle Scholar
• CHARRIER JD: Caspase inhibitors and uses thereof. USPTO (2001).
   Google Scholar
• FRAENKEL CONRAT H: Virology 2nd edn. Prentice Hall, Englewood Cliffs, USA (1998):102–103.
   Google Scholar
• CARR SF, PAPP E, VVU JC, NATSUMEDA Y: Characterization of human type I and type II IMP dehydrogenases. Biol. Chem. (1993) 268(36):27286–27290.
   Google Scholar
• NISHIMURA SI, NISHI N, TOKURA S: Inhibition of the hydrolytic activity of thrombin by chitin heparinoids. Carbohydrate Res. (1986) 156:286–292.
   PubMed Web of Science ®Google Scholar
• LINHARDT RI, TOIDA T: Heparin Analogs - Development and Applications. In: Carbohydrates as Drugs Witczak ZB, Nieforth KA (Eds), Marcel Dekker, New York (1997)7:277–341.
   Google Scholar
• SCULLY MF, VVEERASINGHE KM, ELLIS V, DJAZAERI B, KAKKAR VV: Anticoagulant and antiheparin activities of a pentosan polysulfate. Thrombosis Res. (1983) 31(1):87–97.
   PubMedGoogle Scholar
• OSHIMA G: Trigger action of dextran sulfate on inactivation of thrombin.. Thrombos Res. (1988) 49(3):353–361.
   Google Scholar
• DE CLERCQ: Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. (1993) 42:1–55.
   PubMed Web of Science ®Google Scholar
• LORENTSEN, KJ, HENDRIX CW, COLLINS JM et al.: Dextran sulfate is poorly absorbed after oral administration. Ann. Intern. Med. (1989) 111(7):561–566.
   PubMedGoogle Scholar
• REYNOLDS JEF: The Extra Pharmacopeia. The Pharmaceutical Press, London, UK. 343.
   Google Scholar
• RUSCONI S, MOONIS M, MERRILL DP et al.: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. (1996) 40(1):234–236.
   PubMed Web of Science ®Google Scholar
• HAWKING F: Suramin: with special reference to onchocerciasis. Adv. Pharmacol Chemother. (1978) 15:289–322.
   PubMedGoogle Scholar
• MITCHELL MA, WILKS 1W: Inhibitors of angiogenesis. Ann. Reports in Med. Chem. Academic Press, San Diego (1992):27.
   Google Scholar
• MARKS RM, LU H, SUNDARESAN R et al.: Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. Med. Chem. (2001) 44::2178–2187.
   Google Scholar
• DE CLERCQ E: Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. (1979) 8(1):9–22.
   PubMedGoogle Scholar
• OJALA WH, SUDBECK EA, LU LK, RICHARDSON TI, LOVRIEN RE, GLEASON WB: Complexes of lysine, histidine and arginine with sulfonated azo dyes: model systems for understanding the biomolecular recognition of glycosaminoglycans by proteins. Am. Chem. Soc. (1996) 118(9):2131–2142.
   Google Scholar
• TAN GT, WICKRAMASINGHE A, VERMA S et al: Potential anti-AIDS naphthalenesulfonic acid derivatives. Med. Chem. (1992) 35(26):4846–4853.
   Google Scholar
• BABA M, KONNO K, SHIGETA S, WICKRAMASINGHE A, MOHAN P: Selective inhibition of human cytomegalovirus replication by naphthalenedisulfonic acid derivatives. Antiviral Res. (1993) 20(3):223–233.
   PubMedGoogle Scholar
• KISILEVSKY R, LEMIEUX LJ, FRASER PE, KONG X, HULTIN PG, SZAREK WA: Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulfates implications for Alzheimer's disease. Nat. Med. (1995) 1(2):143–148.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, SZABO S, STOVROFF M, MCNEIL P, LI W, SHING Y: Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann. Stag. (1991) 214(4):414–427.
   Google Scholar
• LINHARDT RI: Polysaccharide lyases for glycosaminoglycan analysis. In: Current protocols in molecular biology: analysis of glycoconjugates. Wiley Interscience, Boston (1994):17.13.17–17.13.32.
   Google Scholar
• TOIDA T, HILEMAN RE, SMITH AE, VLAHOVA PI, LINHARDT RI: Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites. Biol. Chem. (1996) 271(50)32040–32047.
   Google Scholar
• PERVIN A, GALLO C, JANDIK K, HAN XI, LINHARDT RI: Preparation and structural characterization of large heparin-derived oligosaccharides. Clycobiology (1995) 5(1):83–95.
   PubMedGoogle Scholar
• HILEMAN RE, SMITH AE, TOIDA T, LINHARDT RI: Preparation and structure of heparin-lyase derived heparan sulphate oligosaccharides. Clycobiology (1997) 7(2):231–239.
   PubMedGoogle Scholar
• ZHANG F, FATH M, MARKS R, LINHARDT RI: A highly stable covalent conjugated heparin biochip for heparin- protein interaction studies. Anal. Biochem. (2002) 304: 271–273.
   PubMed Web of Science ®Google Scholar
• PAUWELS R: Methods. J. Viro/. (1988) 20:309–321.
   Google Scholar
• ZAMECNIK PC, STEPHENSON ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Sci. (1978) 75(1):280–284 & 285–288.
   Google Scholar
• SANCHEZ I, GOMEZ-GARIBAY F, TABOADAJ, RUIZ BH: Antiviral effect of flavonoids on the dengue virus. Phytother. Res. (2000) 14(2):89–92.
   PubMed Web of Science ®Google Scholar
• SOLER F, POUJADE C, EVERS M et al: Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. Med. Chem. (1996) 39(5):1069–1083.
   Google Scholar
• CALLEBAUT C, JACOTOT E, GUICHARD G et al.: Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death. Virology (1996) 218(1):181–192.
   PubMedGoogle Scholar
• JOHNSON RK, AEON T, GOLDEN A et al: NSC No. 224131. Div. Cancer Treatment. National Cancer Institute, Bethesda (1977).
   Google Scholar
• COHEN J: How DNA shuffling works. Science (2001) 13:239.
   Google Scholar